Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii plus vancomycin/metronidazole vs antibiotics alone in UC with Clostridium difficile infection
ChiCTR2500109901Phase 4Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Sep 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of saccharomyces boulardii, vancomycin and metronidazole in Clostridioides difficile colitis (CDI) and autoimmune colitis (4 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoints: Clostridium difficile toxin B negativization rate and Clostridium difficile infection recurrence rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
saccharomyces boulardiivancomycinmetronidazole
03
Conditions
Clostridioides difficile colitis (CDI)autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2500109901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109901.